B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon‐γ

Abstract

Aims: An important consideration in the design of a tumour vaccine is the ability of tumour‐specific cytotoxic T lymphocytes (CTL) to recognise unmanipulated tumour cells in vivo. To determine whether B‐CLL might use an escape strategy, the current studies compared B‐CLL and normal B cell MHC class I expression.

Methods: Flow cytometry, TAP allele PCR and MHC class I PCR were used.

Results: While baseline expression of MHC class I did not differ, upregulation of MHC class I expression by B‐CLL cells in response to IFN‐γ was reduced. No deletions or mutations of TAP 1 or 2 genes were detected. B‐CLL cells upregulated TAP protein expression in response to IFN‐γ. Responsiveness of B‐CLL MHC class I mRNA to IFN‐γ was not impaired.

Conclusions: The data suggest that MHC class I molecules might be less stable at the cell surface in B‐CLL than normal B cells, as a result of the described release of β₂m and β₂m‐free class I heavy chains from the membrane. This relative MHC class I expression defect of B‐CLL cells may reduce their susceptibility to CTL lysis in response to immunotherapeutic approaches.

• Human
• B‐CLL
• antigen presentation
• MHC class I
• TAP